Roche Respiratory

Weave your way over to ERS Congress 2024

7-11 Sept | Vienna, Austria

header-image
header-image

Join our ERS Congress 2024 Industry Lunchtime Symposium on 'Sounding the ALARM-in COPD'


Mon 9th Sept 12:45-13:45 CEST or visit booth C7.01 in Hall B.

Can we untangle the complexity of COPD?

Can we untangle the complexity of COPD?

Register your interest to find out more about Roche in Respiratory

If you would like to receive communications related to Roche Respiratory publications, events and website updates, please register your interest.

 

By submitting this form, you are giving consent for F.Hoffmann-La Roche Ltd (Roche) to process the personal information provided by you in this form. This processing is necessary for the management of the mailing list and for sending you information, including publications, newsletters, future events, etc. Your personal information will be retained for a period of one year from the date of collection.

 

You have the option to unsubscribe from any communication at any time by simply clicking on the unsubscribe link (integrated in all emails). Furthermore, to exercise any of your privacy rights, please contact Roche at global.privacy@roche.com. For further information, please consult Roche’s privacy notice.

All fields are required

Register

Thank you for registering

Reducing exacerbations is still a major challenge in the treatment of COPD1,2

COPD is a chronic respiratory disease characterised by progressive airway inflammation, yet traditional therapies, such as bronchodilators and corticosteroids, do little to target the underlying biology.3-5

 

Every exacerbation causes lasting lung damage, contributing to disease progression and increasing a patient’s risk of hospitalisation or death, as well as significantly impacting their ability to live their life.6-9

 

In addition, every exacerbation increases the risk of the next exacerbation.6

exacerbation-graph
exacerbation-graph

Up to 51% of patients with a history of exacerbations continue to suffer from exacerbations, even with current therapies.*10

 

*moderate or severe.

COPD is a heterogeneous disease involving both neutrophilic (Types 1 & 3) and eosinophilic (Type 2) inflammation4,5,11–15

Neutrophilic inflammation is the predominant type in the vast majority of patients and, with its central role in pathogenesis, remains the greatest unmet need in COPD treatment.4,5,12,14–16 

 

Understanding how we could address neutrophilic inflammation as well as eosinophilic inflammation could be key to reducing exacerbations across a broader population of patients.5,16

ST2/IL-33 works upstream to drive both eosinophilic and neutrophilic inflammation13,17

Following exposure to tobacco smoke, bacteria and viruses, damaged lung epithelial cells release a number of different alarmins, one of which is IL-33 - an ST2 receptor-mediated cytokine.13,17

 

Binding of IL-33 to the ST2 receptor, expressed across a broad range of immune cells, initiates and amplifies multiple downstream inflammatory pathways that contribute to both neutrophilic (Type 1 and 3) and eosinophilic (Type 2) inflammation.13,17

graph
Download

Studies to explore the impact of targeting the ST2/IL-33 pathway in a broad population of 
COPD patients are ongoing.18–24

Want to stay up to date on all the latest from Roche in Respiratory?

Register your interest here

References

  1. Vogelmeier CF et al. Respir Med 2020:166:105938.
  2. Franssen FM et al. Int J Chron Obstruct Pulmon Dis 2019;14:1465–1484.
  3. Yang H et al. BMJ Open Respir Res 2023;10(1):e001597.
  4. Barnes PJ. Allergy 2019;74(7):1249–1256.
  5. Cazolla M et al. Int J Chron Obstruct Pulmon Dis 2023:18:1333–1352.
  6. Suissa S et al. Thorax 2012;67(11):957–63.
  7. Hurst et al. Eur J Intern Med 2020:73:1–6.
  8. Machado et al. Pulmonology 2023;29(6):518–534.
  9. Titmarsh S et al. Int J Chron Obstruct Pulmon Dis 2019;14:2799–2807.
  10. Halpin D et al Eur Respir J 2020;55(5):1901–921.
  11. Brightling C & Greening N. Eur Respir J 2019;54(2):1900651.
  12. Saha S & Brightling C. Int J Chron Obstruct Pulmon Dis 2006;1(1):39–47.
  13. Calderon AA et al. Eur Respir Rev 2023; 32(167): 220144.
  14. Wen X et al. BMJ Open Respir Res 2023;10(1):e001454.
  15. Kandemir Y et al. Am J Emerg Med 2021:45:237–241.
  16. Butler A et al. COPD 2018;15(4):392–404.
  17. Asrat S et al. J Allergy Clin Immunol 2023;151(2):Suppl AB126
  18. Genentech. ARNASA. Available at https://www.genentech-respiratory-science.com/arnasa.pdf. Accessed August 2024.
  19. ClinicalTrials.gov. Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations (MIRANDA). Available at https://classic.clinicaltrials.gov/ct2/show/NCT06040086. Accessed August 2024.
  20. ClinicalTrials.gov. Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-2). Available at https://classic.clinicaltrials.gov/ct2/show/NCT04751487. Accessed August 2024.
  21. ClinicalTrials.gov. Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/​REGN3500/​Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-1). Available at https://clinicaltrials.gov/study/NCT04701983. Accessed August 2024.
  22. ClinicalTrials.gov. Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations. (TITANIA). Available at https://clinicaltrials.gov/study/NCT05158387?rank=1. Accessed August 2024
  23. ClinicalTrials.gov. Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations (OBERON). Available at https://clinicaltrials.gov/study/NCT05166889?rank=1. Accessed August 2024.
  24. ClinicalTrials.gov. A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (ALIENTO). Available at https://clinicaltrials.gov/study/NCT05037929. Accessed August 2024.

  1. Vogelmeier CF et al. Respir Med 2020:166:105938.
  2. Franssen FM et al. Int J Chron Obstruct Pulmon Dis 2019;14:1465–1484.
  3. Yang H et al. BMJ Open Respir Res 2023;10(1):e001597
  4. Barnes PJ. Allergy 2019;74(7):1249–1256.
  5. Cazolla M et al. Int J Chron Obstruct Pulmon Dis 2023:18:1333–1352.
  6. Suissa S et al. Thorax 2012;67(11):957–63.
  7. Hurst et al. Eur J Intern Med 2020:73:1–6.
  8. Machado et al. Pulmonology 2023;29(6):518–534.
  9. Titmarsh S et al. Int J Chron Obstruct Pulmon Dis 2019;14:2799–2807.
  10. Halpin D et al Eur Respir J 2020;55(5):1901–921.
  11. Brightling C & Greening N. Eur Respir J 2019;54(2):1900651.
  12. Saha S & Brightling C. Int J Chron Obstruct Pulmon Dis 2006;1(1):39–47.
  13. Calderon AA et al. Eur Respir Rev 2023; 32(167): 220144.
  14. Wen X et al. BMJ Open Respir Res 2023;10(1):e001454.
  15. Kandemir Y et al. Am J Emerg Med 2021:45:237–241.
  16. Butler A et al. COPD 2018;15(4):392–404.
  17. Asrat S et al. J Allergy Clin Immunol 2023;151(2):Suppl AB126
  18. Genentech. ARNASA. Available at https://www.genentech-respiratory-science.com/arnasa.pdf. Accessed August 2024.
  19. ClinicalTrials.gov. Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations (MIRANDA). Available at https://classic.clinicaltrials.gov/ct2/show/NCT06040086. Accessed August 2024.
  20. ClinicalTrials.gov. Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-2). Available at https://classic.clinicaltrials.gov/ct2/show/NCT04751487. Accessed August 2024.
  21. ClinicalTrials.gov. Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/​REGN3500/​Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-1). Available at https://clinicaltrials.gov/study/NCT04701983. Accessed August 2024.
  22. ClinicalTrials.gov. Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations. (TITANIA). Available at https://clinicaltrials.gov/study/NCT05158387?rank=1. Accessed August 2024
  23. ClinicalTrials.gov. Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations (OBERON). Available at https://clinicaltrials.gov/study/NCT05166889?rank=1. Accessed August 2024.
  24. ClinicalTrials.gov. A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (ALIENTO). Available at https://clinicaltrials.gov/study/NCT05037929. Accessed August 2024.